Skip to main content
. Author manuscript; available in PMC: 2012 Aug 1.
Published in final edited form as: Clin Cancer Res. 2011 Jun 28;17(15):4975–4986. doi: 10.1158/1078-0432.CCR-10-3328

Figure 4. Inactivation of GSK3β protects against CD27/CD28 loss.

Figure 4

(A) and (B) Tumor-exposed T cells were cultured with medium, IL-7, GSK3β inhibitor X (GSK3β INH), or IL-7 + GSK3β inhibitor X (GSK3β INH+IL-7) for 7 days before staining for CD27/CD28 expression. One representative of the 3 is shown in (A), data from independent 3 experiments are shown in (B), with each bar representing the mean of triplicate values ±SD. (C) T cells alone or tumor-exposed T cells cultured with IL-7 and LY294002 (LY) or AKT inhibitor IV were harvested at the indicated time points. GSK3β phosphorylation was detected by immunolotting with anti-phospho-GSK3β (Ser9) antibody. Blots were re-probed with an anti-GSK3β and anti-β-actin antibodies.